Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 14/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30745084 | 1.00 | PDE5A (0.48) | PDE5AMAPTELANEADORA3KCNH2 | |
| SCHEMBL2881224 | 0.90 | PDE5A (0.42) | PDE5AMAPTELANE | |
| SCHEMBL19126609 | 0.87 | MAPT (0.50) | PDE5AMAPTADORA3KCNH2ATM | |
| SCHEMBL2877930 | 0.86 | ELANE (0.41) | PDE5AMAPTELANE | |
| SCHEMBL2881342 | 0.86 | ELANE (0.41) | PDE5AMAPTELANE | |
| SCHEMBL2882941 | 0.86 | ELANE (0.44) | PDE5AMAPTELANE | |
| SCHEMBL20140295 | 0.86 | ELANE (0.44) | PDE5AMAPTELANE | |
| SCHEMBL2880696 | 0.85 | ELANE (0.40) | PDE5AMAPTELANEADORA3KCNH2 | |
| SCHEMBL6068638 | 0.85 | MAPT (0.47) | MAPTELANE | |
| SCHEMBL20140328 | 0.84 | BUB1 (0.37) | PDE5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1506193-B9 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2026-02-18 | — | — | EP | disclosed |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-1506193-B3 | CARBAMATE-SUBSTITUTED PYRAZOLOPYRIDINES | ADVERIO PHARMA GMBH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-12435080-B2 | sGC stimulators | TISENTO THERAPEUTICS INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-3538096-B1 | TREATMENT OF CNS DISEASES WITH SGC STIMULATORS | TISENTO THERAPEUTICS INC (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-110267658-B | Treatment of CNS disorders with sGC stimulators | 帝善多制药公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2023-11-30 | — | — | US | disclosed |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220017515-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2022-01-20 | — | — | US | disclosed |
| WO-2002042302-A1 | NOVEL SULFONAMIDE-SUBSTITUTED PYRAZOLOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-30 | — | — | WO | disclosed |
| WO-2001083490-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-08 | — | — | WO | disclosed |
| EP-1104421-A1 | 3-(4-AMINO-5-ETHYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO 3,4-B]PYRIDINE | BAYER AG (DE) | 2001-06-06 | — | — | EP | disclosed |
| EP-1102768-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | Bayer Aktiengesellschaft (DE) | 2001-05-30 | — | — | EP | disclosed |
| EP-1102767-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001017998-A2 | METHOD FOR THE PRODUCTION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000066582-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-11-09 | — | — | WO | disclosed |
| WO-2000006569-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBERED HETEROCYCLIC RINGS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006568-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
| WO-2000006567-A1 | 3-(4-AMINO-5-ETHYLPYRIMIDINE-2-YL)-1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE | BAYER AKTIENGESELLSCHAFT (DE) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017515-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885MAPT 4786/4885ELANE 2419/4885 |
| US-11690828-B2 | Treatment of CNS diseases with sGC stimulators | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885MAPT 3160/4885ELANE 2818/4885 |
| US-12435080-B2 | sGC stimulators | GUCY1A2, PRKG1, PDE2A | PDE5A 12/4885MAPT 4786/4885ELANE 2419/4885 |
| US-20230381153-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885MAPT 3160/4885ELANE 2818/4885 |
| US-20260000653-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | PDE9A, PDE2A, GUCY1A2 | PDE5A 8/4885MAPT 1030/4885ELANE 3806/4885 |
| US-20250108040-A1 | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | GUCY1A2, GUCY1B2, PDE2A | PDE5A 11/4885MAPT 3160/4885ELANE 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.